Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Ovarian Cancer Clinical Trial

Official title:

Pamiparib in Combination With Surufatinib in Patients With Platinum-resistant Ovarian Cancer Who Received Prior Poly (ADP-ribose) Polymerase (PARP) Inhibitors: a Multicenter, Single-arm, Phase Ib/II Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05494580
• Other study ID #: B2022-348-01
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: September 22, 2022
• Est. completion date: August 10, 2025

Study information

• Verified date: April 2023
• Source: Sun Yat-sen University
• Contact: Chunyan Lan, M.D.
• Phone: +862087343104
• Email: lanchy[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A number of studies suggest that the combination of PARP inhibitors and antiangiogenic agents produce synergistic activities. Pamiparib is a small molecule inhibitor selectivity for both PARP1 and PARP2. Surufatinib is a novel small-molecule inhibitor that simultaneously targets tumor angiogenesis (via Vascular Endothelial Growth Factor Receptor [VEGFR]1, VEGFR 2, VEGFR3 and Fibroblast Growth Factor Receptor 1 [FGFR1]) and immune evasion (via Colony Stimulating Factor 1 Receptor [CSF1R]). In this trial, we aimed to evaluate the efficacy, safety and tolerability of pamiparib in combination with surufatinib in patients with platinum-resistant ovarian cancer who received prior PARP inhibitors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 38
• Est. completion date: August 10, 2025
• Est. primary completion date: August 10, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Signed Informed Consent Form;

2. Histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer;

3. Platinum-resistant disease, defined as progression within 6 months from completion of most recent platinum-containing therapy. Subject may have been treated with additional regimen(s) subsequent to determination of platinum resistance;

4. Patients must have received one prior PARP inhibitor therapy, and there must be a = 6 month interval since treatment;

5. Female participants age 18-75 years;

6. Has measurable lesion per RECIST v1.1;

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

8. Life expectancy = 3 months;

9. Patients must have normal organ and bone marrow function;

10. Women of childbearing potential should have a negative serum or urine pregnancy test prior to receiving the first dose of study treatment; and should be willing to use one acceptable contraception (i.e., oral contraceptives, condoms, intrauterine devices [IUDs]) throughout the period of taking study treatment and for at least 6 months after the last dose of study drug(s).

Exclusion Criteria:

1. Histological diagnosis of mucinous adenocarcinoma;

2. Has received prior therapy with small molecule antiangiogenic receptor tyrosine kinase inhibitors (TKIs);

3. Known or suspected allergy to any of study drugs;

4. Has clinically significant cardiovascular disease within 6 months from first dose of study intervention, including New York heart association [NYHA] class > 2, unstable angina, myocardial infarction, cardiac arrhythmia associated with hemodynamic instability (including corrected QT (QTc) interval = 450 ms in men, = 470 ms in female);

5. Has active ulcers, gastrointestinal perforation or obstruction;

6. Active bleeding or pathologic condition that carries a high risk of bleeding;

7. Inadequately controlled hypertension (systolic blood pressure = 150 mmHg and/or diastolic blood pressure = 90 mmHg) with or without treatment;

8. Major surgery within 28 days of starting study treatment;

9. Proteinuria = (++) or 24 hours total urine protein > 1.0 g;

10. Uncontrolled pericardial or pleural or peritoneal effusions;

11. Has a diagnosed and/or treated additional malignancy within the last 5 years. Exceptions include in situ cervical cancer, non-melanoma skin cancer, or superficial bladder tumors that has undergone potentially curative therapy;

12. Known Human Immunodeficiency Virus (HIV) infection;

13. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis;

14. Any medical or other condition that in the opinion of the investigator(s) would preclude the participant's participation in the study.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Carcinosarcoma
• Fallopian Tube Carcinosarcoma
• Mixed Tumor, Mullerian
• Ovarian Cancer
• Ovarian Carcinoma
• Ovarian Neoplasms
• Platinum-resistant Ovarian Cancer
• Primary Peritoneal Cancer

Intervention

Drug:
• Pamiparib
Oral
• Surufatinib
Oral

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Cetntre	Guangzhou

Sponsors (2)

Lead Sponsor	Collaborator
Sun Yat-sen University	Hutchmed

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Biomarkers associated with the response to pamiparib combined with surufatinib	To identify the biomarkers, including but not limited to genomic, homologous recombination deficiency (HRD), that predict the efficacy of this study treatment.	from the first drug administration up to two years
Primary	Maximum tolerated dose (MTD) (Phase Ib)	MTD is defined as the highest dose level at which no more than 1 out of 6 subjects experiences a dose limiting toxicity (DLT) during the first cycles. DLT is defined as: grade 3 febrile neutropenia, grade 4 hematologic toxicities, and = grade 3 non-hematologic toxicities that occurred within the first cycle of treatment with pamiparib and surufatinib.	first 21 days of treatment
Primary	Recommended Phase 2 dose (RP2D) (Phase Ib)	Determine the RP2D of the pamiparib and surufatinib combination	first 21 days of treatment
Primary	Response Rate (ORR) (Phase II)	ORR is the proportion of patients with best response of complete response (CR) and partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.	from the first drug administration up to two years
Secondary	Progression-free Survival (PFS)	Time from the date of first study treatment administration to the date of first documented tumor progression or death due to any cause, whichever occurs first.	from the first drug administration up to two years
Secondary	Disease Control Rate (DCR)	Proportion of patients whose best overall response is either CR, PR, or SD.	from the first drug administration up to two years
Secondary	Duration of response (DOR)	Time from first documented response (CR or PR) until documented disease progression or death, whichever occurs first.	from the first drug administration up to two years
Secondary	Overall survival (OS)	Time from the date of first study treatment administration to the date of death due to any cause.	from the first drug administration up to 2 years
Secondary	Safety and tolerability	Incidence, nature, and severity of adverse events graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.	up to 90 days after last study treatment administration
Secondary	Patient Reported Outcomes (PROs)	Determination of changes in PROs with Functional Assessment of Cancer Therapy for patients with ovarian cancer (FACT-O) questionnaire	from the first drug administration up to two years